tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Akari Therapeutics sees cash runway into 2028

Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million. Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1